<DOC>
<DOCNO>EP-0625908</DOCNO> 
<TEXT>
<INVENTION-TITLE>
ANTIDOTE FOR HIRUDIN AND SYNTHETIC THROMBIN INHIBITORS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3800	A61K3800	A61K3843	C12N964	A61K3848	C12N974	C12N974	A61P704	A61K3846	A61P700	C12N964	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	C12N	A61K	C12N	C12N	A61P	A61K	A61P	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61K38	A61K38	C12N9	A61K38	C12N9	C12N9	A61P7	A61K38	A61P7	C12N9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
MAX PLANCK GESELLSCHAFT
</APPLICANT-NAME>
<APPLICANT-NAME>
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUCHA ELKE
</INVENTOR-NAME>
<INVENTOR-NAME>
NOWAK GOETZ
</INVENTOR-NAME>
<INVENTOR-NAME>
BUCHA, ELKE
</INVENTOR-NAME>
<INVENTOR-NAME>
NOWAK, GOETZ
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Antidote to hirudin and to synthetic thrombin 
inhibitors, characterised in that it contains a 

compound which splits prothrombin to meizothrombin, a 
prothrombin intermediate, a pharmacologically 

acceptable salt thereof or a mixture of these 
compounds together with conventional carriers and/or 

diluents, the prothrombin intermediate contained being 
meizothrombin, PIVKA-prothrombin, meizothrombin of 

fragment 1, or a compound containing meizothrombin. 
Antidote according to claim 1, characterised in that 
it contains a snake venom as the compound which splits 

prothrombin to meizothrombin. 
Antidote according to claim 2, characterised in that 
it contains ecarin as the snake venom. 
Antidote according to at least one of claims 1 to 3, 
characterised in that it is in a form suitable for 

parenteral administration. 
Antidote according to claim 4, characterised in that 
it is in a form suitable for subcutaneous, 

intramuscular or intravasal administration. 
Use of a compound which splits prothrombin to 
meizothrombin, of a prothrombin intermediate, of a 

pharmaceutically acceptable salt thereof or of a 
mixture of these compounds together with conventional 

carriers and/or diluents for the preparation of an 
antidote to hirudin and to synthetic thrombin 

inhibitors, with meizothrombin, PIVKA-prothrombin, 
meizothrombin of fragment 1, or a compound containing 

meizothrombin being used as the prothrombin 
intermediate.  

 
Use according to claim 6, characterised in that a 
snake venom is used as the compound which splits 

prothrombin to meizothrombin. 
Use according to claim 7, characterised in that ecarin 
is used as the snake venom. 
Use according to at least one of claims 6 to 8, 
characterised in that an antidote suitable for 

parenteral administration is prepared. 
</CLAIMS>
</TEXT>
</DOC>
